Background: Recurrences of neuroblastoma Evans' stage I-in are infrequent events and the types of its progression have rarely been reported. Therefore, we investigated the patterns of progression in a large series of patients with long follow-up.
Introduction
The prognosis of patients with neuroblastoma depends very much on the stage at diagnosis. While localised disease is associated with a greater than 80% long-term survival [1] [2] [3] , the outcome of metastatic neuroblastoma is around 20% [4] [5] [6] [7] . The two prognostic groups are indistinguishable by histology, but demonstrate distinctive molecular characteristics [8, 9] . Poor prognosis is frequently associated with euploid tumor DNA [10, 11] , deletion of chromosome lp [12, 13] , N-myc amplification [11, 12, 14] and absence of CD44 [15, 16] and trkA [17] expression. Neuroblastomas with good prognosis may be characterized by DNA aneuploidy, neither lp deletion nor N-myc amplification and expression of CD44, trkA. The distinct genetic features of the prognostic groups support the idea of two biological entities of neuroblastoma.
Progression from localised to metastatic disease has rarely been reported in neuroblastoma. This may be due to the facts that neuroblastoma is rare in childhood (1 case/100,000 children under 15 years [17] ) and recurrences from localised disease are even more rare events, confined to single cases in one institution. However, we challenge the concept of a fixed two biological entities with one histology 1 because of the observation of a substantial number of patients progressing from localised to metastatic disease. The data presented here support the idea that early detection of low-stage, laterprogressing neuroblastoma by mass screening programs may be possible.
Patients and methods
We analysed retrospectively the data on 808 consecutive patients of the cooperative German Pediatric Oncology (GPO) neuroblastoma trials NB 79, NB 82, and NB 85. Stage IVs patients (n -76) were not included in this analysis. All surviving children have been followed for a minimum of Eve years. In all cases the diagnosis was established by histological criteria. The Evans' classification was used for staging [18] . Throughout all of the trials the primary tumor was assessed by sonography and CT scans and metastatic disease by "mTc bone scan and plan radiographs for Tc-uptaking lesion. A minimum of 2 bone marrow aspirates were performed in more than 90% of the cases. In 1985 4 aspirates or 2 aspirates plus two tre-phines were recommended, but not always done. The tumor specific catecholamine metabolites vanilmandelic acid and homovanillyl acid were determined in urine or serum, and the risk factor LDH in serum only. In 1985 mlBG scintigraphy and in 1986 immunocytology of bone marrow aspirates were introduced. The newer techniques resulted in improved quantification of the disease, but not in a change of stage incidence (e.g., stage IV incidence NB79: 47.1%, NB82 42.5%, NB85 42.2%).
Risk groups for stage III were defined by the factors serum LDH (elevated for age -unfavorable vs. not elevated -favorable), age (>9 months -unfavorable vs. <9 months -favorable) and tumor resectability (biopsy -unfavorable vs. subtotal or total removalfavorable). Patients with 0 or 1 unfavorable risk factor qualified for the standard risk group (A or B) and those with 2 or 3 unfavorable risk factors for the high risk group (C or D) [19] . N-myc amplification in tumor tissue was determined by Southern blot analysis [12] . Four or more copies of N-myc were defined as amplification.
Surgery was the only treatment for stage I patients in all trials. In stage II local radiotherapy (trial NB 79) or three cycles of low-intensive chemotherapy with adriamycin and cyclophosphamide (NB 82, NB 85) was administered after surgery. Stage HI patients received 3 high-and 6 low-intensive chemotherapy cycles in trial NB 79, 10 cycles of high-intensive chemotherapy in NB 82 (+ 30 Gy local irradiation in instances of a macrocropic residual at the end of therapy), and 4-7 cycles of high-intensive chemotherapy (+ 24-30 Gy local irradiation as above) in trial NB 85. High-intensive chemotherapy included the drugs adriamycin, cyclophosphamide, vincristine, dacarbazine (ACVD), cisplatinum, teniposide (PCVm), ifosfamide and etoposide (IVp) [20] .
The transition time was defined as the period from first neuroblastoma diagnosis to diagnosis of systemic relapse. For KaplanMeier estimates and statistical analysis the BMDP package, version 90 and SPSS for MS Windows Release 5.0 were used. Wilcoxon and X 2 tests were utilized to generate p values without adjustment for risk due to multiple testing because of the exploratory nature of the investigation.
Results
Of 808 patients, 381 children had localised neuroblastoma (Evans stage I-HI: 47.2%, I: 9.4%, II: 20.2%, HI: 27.6%), 351 had stage IV (43.4%) and 76 (9.4%) stage IVs disease. Of 76 stage I patients 6 experienced local and 3 metastatic recurrence. Of 82 stage II children 1 had local and 3 systemic relapse. In 223 cases of stage ITJ neuroblastoma 34 local and 30 metastatic recurrences were observed. The survival rates after more than 12 years were 94 ± 2% for stage I, 95 ± 2% for stage II and 72 ± 3% for stage HI disease. The difference in treatment strategies among the trials did not result in outcome differences, not even in subgroups of stages I, II or in neuroblastoma Irrespective of stage IVs patients, four types of spread were observed during 5-16 years of follow-up:
1 Figure 1 shows the Kaplan-Meier estimates for overall survival. More than 10 years after diagnosis patients with local recurrences had only a 41% survival. The outcome of children with systemic recurrence was 9% and not better than that of patients with initial stage TV (14%). After exclusion of treatment-related deaths the survival ratio was 43 ± 9% for the group with local recurrences, 10 ± 6% for systemic recurrences and 18 ± 2% for initial stage IV neuroblastoma.
N-myc data were available only for a limited number with recurrences from stage I-HI disease, 10/26 (38%) had amplified N-myc oncogene: 4 of 14 (29%) with local relapse only and 6 of 12 (50%) with systemic ± local relapse. All patients with N-myc amplification died including 1 with local relapse who succumbed to toxic effects. Of the patients whose neuroblastomas were without N-myc amplification 2/10 with local and 4/7 with metastatic recurrences died of tumor progression. Consecutive investigations were done in 3 patients. A change in the N-myc copy number between initial and recurrence diagnosis was not seen. Figure 2 demonstrates that the age at diagnosis was different among the groups. Patients with localised neuroblastoma and no recurrences at all were 10 months (median) at diagnosis. This contrasted to 19 months for children with local recurrences and 43 months for patients presenting later with metastatic recurrences (p < 0.001) for all combinations. The median age at initial metastatic neuroblastoma was 33 months (not different from recurrent metastatic disease). Diagnosis in infancy did not exclude later local (11/41) or systemic (5/37) recurrences. The primary tumor of stage I-m neuroblastoma originated most frequently from adrenals (37.2%) and from other intraabdominal sites (31.7%). Thoracic primaries were found in 18.6% and cervical primaries in 7.2% of the cases. Combined (e.g., thoracic/abdominal) and other sites were present in 5.4%. No patient with a thoracic primary later demonstrated a systemic recurrence. Other features characteristic of the type of spread were not detected.
Metastatic recurrences following initially localised neuroblastoma more frequently included distant lymph nodes (39 vs. 21%) and less frequently bone marrow (41 vs. 81%) and bone (37 vs. 59%) compared to initial stage IV metastatic sites (Fig. 3) . Nonetheless, the patterns of metastases were similar in systemic relapse from stages I-m and from stage IV disease (bone marrow 41 vs. 41%, bone 37 vs. 54%, intracranial 14 vs. 16%).
With respect to missing molecular data other than N-myc we investigated the power of clinical risk factors to predict the outcome. The incidence of abnormal serum LDH levels correlated well with the risk of recurrences (no recurrences: 33% abnormal LDH, local recurrences: 55.2%, metastatic recurrences 80.8%, primary metastatic disease 89.6%) (p < 0.001). Likewise the risk estimation using risk groups as defined for stage m (67/77 = 83%) predicted the biological behaviour relatively well: high-risk-group patients were found in 31% of those in the group without recurrences, in 57.7% of those with local and in 80.0% of those with metastatic recurrences.
Discussion
Reports on the outcome of patients with localised neuroblastoma have uniformly demonstrated good results, with survival ratios in the range of 80% and more [1] [2] [3] , but have not referred to the pattern of failure (local vs. metastatic tumor progression, treatment- related death). Here we report in a large series of patients (381 patients of stage I-m) with a long followup (5-16 years) that 47% of recurrences show true metastatic spread comparable to that in children with stage IV disease. It cannot be discounted that patients with systemic recurrence may have been understaged at first diagnosis, i.e., metastatic disease was already present but not found, for instance, in bone marrow at non-sampling sites or in small lymph nodes. However, the constant incidence figures of stage IV disease throughout the recent 16 years with continuously improved diagnostic tools argues against that possibility. The outcome of patients with systemic recurrence was as poor as that of children with initial stage IV disease. Even local progression was associated with only a 41% survival. In our series patients with cervical neuroblastoma did not present systemic metastasis initially, but rather at the time of relapse, while thoracic primaries were associated with distant tumor sites at first diagnosis but not at relapse. This observation is noteworthy, but may be related to the limited number of patients in this study.
Children with systemic recurrences were significantly older (43 months) at first diagnosis than patients with local relapse (19 months). The locally relapsing children were older at diagnosis than patients who never relapsed (10 months). The median age of stage IV patients (33 months) was comparable to that of those who presented distant metastases at recurrence. The data suggest that increasing age is associated with more malignant disease. This is in agreement with an earlier observation of a close correlation between age and stage (median age of stage I: 7 months, II: 7.5 months, HI: 20 months, IV: 34 months) [21] . It appears that time enhances the malignant process by allowing additional genetic events to occur. N-myc amplification and possibly lp deletion are certainly late events in the progression toward malignancy. Markers for earlier genetic events are currently unknown, but would provide better insight into the supposed multistep process as seen in other human tumors such as astrocytoma [22] . However, since suitable markers for neuroblastoma and direct evidence from serial determinations in individual cases are lacking, the possibility of fixed biological entities with one histology cannot be discounted. In our opinion the observation of systemic progression in nearly half of the patients who relapsed from localised disease support the idea that stage IV disease in older children may derive from earlier but undetected localised neuroblastoma in a substantial fraction. Screening programs performed at a point in time when natural regression processes are considered to be almost over (e.g., at 1 year of age) are likely to show whether the concept of stepwise progression or of fixed entities is more accurate. The interval from first diagnosis to the appearance of metastasis (median 13 months) suggests the existence of a reasonably long diagnostic window for early detection of neuroblastoma.
